Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial

Published:2017-01-12 Issue:1 Volume:56 Page:129-143
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Boada Mercè¹²,Anaya Fernando³,Ortiz Pilar⁴,Olazarán Javier⁵,Shua-Haim Joshua R.⁶,Obisesan Thomas O.⁷,Hernández Isabel¹,Muñoz Joan⁴,Buendia Mar¹,Alegret Montserrat¹,Lafuente Asunción¹,Tárraga Lluís¹,Núñez Laura⁸,Torres Mireia⁸,Grifols Joan Ramon⁴,Ferrer Isidre⁹,Lopez Oscar L.¹⁰,Páez Antonio⁸

Affiliation:

1. Memory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain

2. Neurology Service, Hospital General Universitari Vall d’Hebron, Barcelona, Spain

3. Nephrology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain

4. Banc de Sang i Teixits, Barcelona, Spain

5. Neurology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain

6. Alzheimer’s Research Corporation, Mid Atlantic Geriatric Association, Manchester, NJ, USA

7. Department of Internal Medicine, Howard University, Washington, DC, USA

8. Clinical Trials Department, Instituto Grifols S.A., Barcelona, Spain

9. Institut de Neuropatologia, Hospital Universitario Bellvitge, Barcelona, Spain

10. Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference50 articles.

1. Incidence and prevalence of dementia in the Cardiovascular Health Study;Fitzpatrick;J Am Geriatr Soc,2004

2. The natural history of Alzheimer’s disease. Description of study cohort and accuracy of diagnosis;Becker;Arch Neurol,1994

3. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease;Hyman;Alzheimers Dement,2012

4. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease;Salloway;N Engl J Med,2014

5. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease;Doody;N Engl J Med,2014

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-08

2. Revolutionizing Alzheimer's treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements;Ageing Research Reviews;2024-08

3. Association between Body Mass Index or Serum Albumin and Different Dementia Populations;European Neurology;2024-07-30

4. Blood-based therapies to combat neurodegenerative diseases;Metabolic Brain Disease;2024-06-06

5. In Search for Low-Molecular-Weight Ligands of Human Serum Albumin That Affect Its Affinity for Monomeric Amyloid β Peptide;International Journal of Molecular Sciences;2024-05-02